sparsentan   Click here for help

GtoPdb Ligand ID: 8448

Synonyms: DARA-a (Dual Acting Receptor Antagonist of angiotension and endothelin receptors) | BMS-346567 | compound 7 [PMID 15634011] | Filspari® | RE-021 | retrophin
Approved drug Immunopharmacology Ligand
sparsentan is an approved drug (FDA (2023))
Compound class: Synthetic organic
Comment: Sparsentan (RE-021) is a selective dual-acting receptor antagonist with affinity for endothelin (A type) and angiotensin II receptors (Type 1) [5-6]. Sparsentan combines the active moieties of the selective AT1 receptor antagonist irbesartan and a selective ETA receptor antagonist (see ligand 91 in [5]).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 12
Topological polar surface area 122.48
Molecular weight 592.27
XLogP 5.9
No. Lipinski's rules broken 2
Click here for help
Canonical SMILES CCCCC1=NC2(C(=O)N1Cc1ccc(c(c1)COCC)c1ccccc1S(=O)(=O)Nc1noc(c1C)C)CCCC2
Isomeric SMILES CCCCC1=NC2(C(=O)N1Cc1ccc(c(c1)COCC)c1ccccc1S(=O)(=O)Nc1noc(c1C)C)CCCC2
InChI InChI=1S/C32H40N4O5S/c1-5-7-14-29-33-32(17-10-11-18-32)31(37)36(29)20-24-15-16-26(25(19-24)21-40-6-2)27-12-8-9-13-28(27)42(38,39)35-30-22(3)23(4)41-34-30/h8-9,12-13,15-16,19H,5-7,10-11,14,17-18,20-21H2,1-4H3,(H,34,35)
Immunopharmacology Comments
Sparsentan is approved as a treatment for the immune disease primary IgA nephropathy (IgAN; Berger's disease). IgAN is characterised by deposition of IgA in the glomeruli with associated inflammation of the glomeruli (glomerulonephritis). The condition can cause hematuria and proteinuria, and occasionally kidney failure in severe cases.